Clinical Trials Logo

Filter by:
NCT ID: NCT00851721 Completed - Hemophilia A Clinical Trials

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Start date: March 31, 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study was to determine the efficacy, safety, and health-related quality of life benefits with FEIBA NF prophylactic treatment as compared with on-demand treatment.

NCT ID: NCT00851240 Completed - Clinical trials for Rheumatoid Arthritis

BTT-1023 in Rheumatoid Arthritis

Start date: February 2009
Phase: Phase 1
Study type: Interventional

Patients with adult-onset rheumatoid arthritis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed. The patient allocation to treatment groups will occur at random, and the actual treatment will not be revealed to the investigator or to the patient during the trial.

NCT ID: NCT00847613 Completed - Clinical trials for Arthritis, Rheumatoid

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

Start date: March 2009
Phase: Phase 3
Study type: Interventional

This study is designed to provide safety and efficacy data to support the development of CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of methotrexate.

NCT ID: NCT00844662 Terminated - Clinical trials for Chronic Kidney Failure

Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride

Start date: July 2009
Phase: Phase 3
Study type: Interventional

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring haemodialysis, compared with a marketed phosphate binder, sevelamer hydrochloride.

NCT ID: NCT00838773 Active, not recruiting - Behavior Clinical Trials

International Social Network Intervention

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This grant involves 24 social networks of young men who have sex with men, Roma, and young high-risk heterosexual adult men and women living in Hungary, Bulgaria and Russia.

NCT ID: NCT00835770 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

ENDORSE
Start date: February 3, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

NCT ID: NCT00831441 Terminated - Clinical trials for Acute Coronary Syndrome

Phase III Acute Coronary Syndrome

APPRAISE-2
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome

NCT ID: NCT00829166 Active, not recruiting - Breast Cancer Clinical Trials

An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer

EMILIA
Start date: February 2009
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib for HER2-positive metastatic breast cancer (MBC). Patients were treated until disease progression, unmanageable toxicity, or study termination. Once disease progression was reported, all patients were followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

NCT ID: NCT00825058 Completed - Clinical trials for Major Depressive Disorders

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Start date: November 2003
Phase: Phase 3
Study type: Interventional

Primary objective : - To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode. Secondary objectives: - To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.

NCT ID: NCT00824460 Completed - Clinical trials for Chronic Kidney Disease

Study of Phosphate Levels in Patients With Chronic Kidney Disease

PA21
Start date: December 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the ability of different doses of PA21 to lower serum phosphate levels, in patients with chronic kidney disease on maintenance hemodialysis.